C92.02
Acute myeloblastic leukemia, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Acute myeloblastic leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow, characterized by the rapid increase of abnormal myeloblasts — immature blood cells that should normally develop into healthy white blood cells. When AML enters a relapse phase, it means the disease has returned after an initial period of recovery. The specific ICD-10 code C92.02 is used to classify cases of AML that have relapsed, indicating a need for ongoing medical management and treatment.
Causes & Symptoms
Clinical Causes: Genetic mutations: Alterations in DNA within blood cells can lead to uncontrolled growth. Previous chemotherapy or radiation therapy: Treatments for other cancers may increase the risk of AML relapse. Environmental exposures: Contact with certain chemicals or toxins, like benzene, may contribute. Pre-existing blood disorders: Conditions such as myelodysplastic syndromes can evolve into AML. Familial genetic factors: A family history of leukemia can increase susceptibility.
Key Symptoms: Persistent fatigue or weakness Unexplained fever or infections Unusual bleeding or bruising Shortness of breath Pale skin Bone or joint pain Frequent or severe infections Swollen lymph nodes or spleen Unintended weight loss
Diagnostic & Treatment
Diagnosis Path: Blood tests: Complete blood count (CBC) to detect abnormal levels of blood cells. Bone marrow biopsy: Extracting a sample from the bone marrow to examine for leukemia cells. Cytogenetic analysis: Checking for chromosomal abnormalities associated with AML relapse. Molecular testing: Identifies genetic mutations linked to disease progression. Imaging studies: Such as CT scans to assess the presence of disease in other organs.
Treatment Protocols: Chemotherapy: Intensive drug therapy aimed at destroying leukemia cells. Targeted therapies: Medications designed to focus on specific genetic mutations within the cancer cells. Stem cell transplant: Replacing diseased bone marrow with healthy stem cells to reset blood cell production. Supportive care: Including blood transfusions, antibiotics, and growth factors to manage symptoms and prevent complications. Clinical trials: Access to new and emerging treatments that may be effective against relapsed AML.
Clinical Advice & FAQs
Billing Guidance
Is C92.02 a billable ICD-10 code?
Yes, C92.02 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.02?
Clinical documentation must specify the nature of Acute myeloblastic leukemia, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference